Kidney Stones Up Kidney Cancer Risk
According to investigators, kidney stones are associated with an increased risk of papillary renal cell carcinoma (RCC) and upper tract urothelial carcinoma (UTUC).01/02/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 2, 2019 Category: Urology & Nephrology Source Type: news
MSKCC Risk Stratification Model in RCC Updated to Include Genomic Information
The Memorial Sloan Kettering Cancer Center (MSKCC) risk stratification model in advanced renal cell carcinoma (RCC) currently used in clinical practice stratifies patients into risk groups of favorable, intermediate, and poor.12/28/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 28, 2018 Category: Urology & Nephrology Source Type: news
Clinicopathological Features and Survival Data of Localized Renal Masses in Young Adults
According to a study that was done by the Asian Pacific Journal of Cancer Prevention, the overall survival rate of young adults (ages 18-40 years old) with localized renal masses is 93.8%.12/26/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 27, 2018 Category: Urology & Nephrology Source Type: news
Cancer research legend urges patients to get multiple opinions
National Cancer Institute Chief of Surgery Steven Rosenberg recommends seeking out multiple professional opinions to confirm a diagnosis and to figure out what your best options are.12/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 27, 2018 Category: Urology & Nephrology Source Type: news
Optimizing Combinations Next Challenge in mRCC
As the treatment paradigm for metastatic renal cell carcinoma (mRCC) continues to evolve, combination therapy is likely to be an important part of the future, said Bradley G. Somer, MD.12/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 21, 2018 Category: Urology & Nephrology Source Type: news
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre
Bone metastases (BMs) are associated with significant morbidity and shorter survival in renal cell carcinoma (RCC). Our purpose was to identify prognostic factors for overall survival (OS) in RCC patients with BMs.12/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 20, 2018 Category: Urology & Nephrology Source Type: news
Future Directions for RCC Research
Dr. Brian Rini and Dr. David McDermott explain what âs next in kidney cancer research.12/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 20, 2018 Category: Urology & Nephrology Source Type: news
Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies
Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse.12/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2018 Category: Urology & Nephrology Source Type: news
Life threatening toxicities of chemotherapies and immunomodulating medications
Life threatening toxicities of chemotherapies and immunosuppressants can occur with varying frequency depending on the agent suspected and underlying patient risk factors. It is important for clinicians to remember that these medications can be the cause or contributor to many important complications that occur in the ICU.12/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2018 Category: Urology & Nephrology Source Type: news
Immediate Surgery No Help in Metastatic RCC
Treating metastatic kidney cancer with immediate cytoreductive nephrectomy (CN) did not ward off disease progression, the randomized SURTIME trial confirmed.12/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2018 Category: Urology & Nephrology Source Type: news
Treatment of Stage IV Kidney Cancer
Patients with Stage IV renal cell cancer have cancer that has spread to distant sites in the body, invaded directly into local structures, or has spread to more than one lymph node. Stage IV disease is also known as metastatic cancer.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news
Treatment of Stages I - III Kidney Cancer
Patients with Stage I renal cell cancer have a primary cancer that is less than 7 centimeters in size (about 3 inches). The cancer is limited to the kidney, and has not spread to lymph nodes or distant sites.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news
Treatment & Management of Kidney Cancer
Treatment for renal cell cancer is tailored to each individual and may include surgery, precision cancer medicines, immunotherapy and chemotherapy. Radiation therapy is not typically used for the treatment of renal cell cancer. The specific treatment depends on the stage and genomic profile of the cancer.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news
Cancer Deaths on the Decline
Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute.12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news
Keytruda- Inlyta Treatment Combination Improves Outcomes in Renal Cell Caner
The pivotal Phase 3 KEYNOTE-426 clinical trial investigating Keytruda (pembrolizumab) anti-PD-1 therapy in combination with Inlyta (axitinib), a tyrosine kinase inhibitor (TKI) improved both overall survival (OS) and delayed the time to cancer progression compared to Sutent (sunitinib) when used in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC).12/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2018 Category: Urology & Nephrology Source Type: news
